Skip to main content
SpringerLink
Log in

N-Terminal-proBNP (NT-proBNP) as an indicator of cardiac dysfunction

A study in patients presenting with suspected cardiac disorders

N-Terminales-proBNP (NT-proBNP)—Ein Indikator für kardiale Dysfunktion

  • ORIGINAL PAPER
  • Published:
Zeitschrift für Kardiologie Aims and scope Submit manuscript

Zusammenfassung

Natriuretische Peptide stellen eine neue Möglichkeit in der Bewertung der kardialen Dysfunktion dar. In dieser Studie wurde NT-proBNP bei 473 Patienten, die sich bei 18 Kardiologen vorstellten, zusätzlich zur Standarddiagnostik wie Anamnese, klinischer Untersuchungsbefund, Elektrokardiogramm und Echokardiogramm untersucht. NT-proBNP korrelierte zur linksventrikulären Auswurf-Fraktion (LVEF), der NYHA Klassifikation, Angina Pectoris und Myokardinfarkt in der Anamnese, Vorhofflimmern, Schilddrüsen- und Nierenfunktion. Die Studie zeigt, dass NT-proBNP zur Diagnostik der kardialen Dysfunktion einen wesentlichen Beitrag leistet.

Summary

Background

Natriuretic peptides represent a novel diagnostic tool in the assessment of cardiac dysfunction.

Methods

A total of 473 consecutive referred patients presenting to 18 cardiologists for the assessment of their cardiac state were recruited for the study. Patients received a medical history, a physical examination an electrocardiogram and an echocardiogram where left ventricular ejection fraction was recorded.

Results

NT-proBNP was found to correlate with left ventricular ejection fraction (LVEF), level of symptoms (NYHA classification), history of angina pectoris (AP) and myocardial infarction (AMI). Atrial fibrillation (AF) and thyroid dysfunction as well as renal impairment were shown to influence NT-proBNP levels.

Conclusion

The study supports the hypothesis that NT-proBNP determination contributes to the assessment of patients presenting to cardiologists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Huldeman GA, Croft JB, Giles WH, Rashidee A (1999) Hospitalization of patients with heart failure; National Hospital Discharge Survey, 1985 to 1995. Am Heart J 137(2):352–360

    Google Scholar 

  2. Hoes AW, Mosterd A, Grobbee DE (1998) An epidemic of heart failure? Recent evidence from Europe. Eur Heart J19:L2–9

    Google Scholar 

  3. Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22:6A–13A

    CAS  PubMed  Google Scholar 

  4. Krum H, Gilbert RE (2003) Demographics and concomitant disorders in heart failure. Lancet 362:147–158

    Google Scholar 

  5. The Task Force on Heart Failure of the European Society of Cardiology (1995) Guidelines for the diagnosis of heart failure. Eur Heart J 16 :741–751

    Google Scholar 

  6. Sundsfjord JA, Thibault G, Larochelle P, Cantin M (1988) Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 66(3):605–610

    Google Scholar 

  7. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD (1996) Comparison of atrial natriuretic peptide, b-type natriuretic peptide and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 77:828–831

    Google Scholar 

  8. Levin ER, Gardner DG, Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321–328

    Article  CAS  PubMed  Google Scholar 

  9. Raizada V, Thakore K, Luo W, McGuire PG (2001) Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 216(1–2):137–140

    Google Scholar 

  10. Hall C (2004) Essential biochemistry and physiology of (NT-pro) BNP. European Journal of Heart failure 6:257–260

    Google Scholar 

  11. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA (1997) Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): A new marker of cardiac impairment. Clin Endocrinol 47:287–296

    Google Scholar 

  12. Hughes D, Talwar S, Squire IB, Davies JE, Ng LL (1999) An immunoluminometric assay for N-terminal probrain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci 96:373–380

    Google Scholar 

  13. Clerico A, Del Ray S, Giannessi D (2000) Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: The need for a new generation of immunoassay methods. Clin Chem 46:1529

    Google Scholar 

  14. Talwar S, Downie PF, Ng LL, Squire IB (2000) Towards a blood test for heart failure: The potential use of circulating natriuretic peptides. Br J Clin Pharmacol 50:15–20

    Google Scholar 

  15. Yeo J, Wu A, Apple F, Kroll M, Christenson R, Lewandrowski K et al (2003) A Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338:107–115

    CAS  PubMed  Google Scholar 

  16. Schulz H, Langvik TA, Lund Sagen E, Smith J, Ahmadi N, Hall C (2001) Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest 61:33–42

    Google Scholar 

  17. Sagnella GA (2001) Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem 38:83–93

    Google Scholar 

  18. Mair J, Hammerer-Lercher A, Puschendorf B (2001) The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 39:571–588

    Google Scholar 

  19. Clerico A, Emdin M (2004) Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50(1):33–50

    Google Scholar 

  20. Yandle TG, Nicholls GM, Richards AM (2002) Brain natriuretic peptide-Its function and diagnostic application. Clin Biochemist Rev 23:3–21

    Google Scholar 

  21. de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 361:9370

    Google Scholar 

  22. McCullough PA, Omland T, Maisel AS (2003) B-type natriuretic peptides: a diagnostic breakthrough for clinicians, Vol. 4 No. 2. Reviews in Cardiovascular Medicine 4(2):72–80

    Google Scholar 

  23. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R et al (2003) Clinical applications of B-type natriuretic peptide (BNP) testing. European Heart Journal 24:1710–1718

    Google Scholar 

  24. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A (2004) Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the propeptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide. Clin Chem Lab Med 42(1):37–44

    Google Scholar 

  25. Bruch C, Schmermund A, Dagres N et al (2002) Tel-Index in coronary artery disease-validation in patients with overall cardiac and isolated diastolic dysfunction. Z Kardiol 91(6):472–480

    Article  Google Scholar 

  26. Koglin J (2000) Pathogenetic mechanisms of cardiac allograft vasculopathy-impact of nitric oxide. Z Kardiol 89(Suppl 9):IX24–IX27

    Google Scholar 

  27. Olson MH, Wachtell K, Tuxen C, Hildebrandt P (2004) N-terminal probrain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy. A LIFE study. J Hypertens 22(8):1597–1604

    Google Scholar 

  28. Luchner A, Hengstenberg C, Löwel H, Trawinski J, Baumann M, Riegger GAJ et al (2002) N-terminal pro-brain natriuretic peptides after myocardial infarction: A marker of cardio-renal function. Hypertension 39:99–104

    Google Scholar 

  29. Wahl HG, Graf S, Renz H, Fassbinder W (2004) Elimination of the cardiac natriuretic peptide (BNP) and N-Terminal proBNP by hemodialysis. Clin Chem (6):1071–1074

    Google Scholar 

  30. Ortega O, Gallar P, Munoz M, Rodriguez I, Carreno A, Ortiz M et al (2004) Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in predialysis patients. Nephron Clin Pract 97(4):C125–C30

    Google Scholar 

  31. Schultz M, Faber J, Kistorp C, Jarlov A, Pedersen F, Wiinberg N, Hildebrandt P (2004) N-terminal-pro-Btype natriuretic peptide (NT-proBNP) in different thyroid function states. Clin Endocrinol 60(1):54–59

    Google Scholar 

  32. Svendstrup Nielsen L, Svanegaard J, Klitgaard NA, Egeblad H (2004) N-terminal-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. European Journal of Heart failure 6(1):63–70

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Roche Diagnostics GmbH, Sandhofer Str. 116, 68305, Mannheim, Germany

    G. Hess, J. Moecks & D. Zdunek

Authors
  1. G. Hess
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Moecks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Zdunek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Hess.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hess, G., Moecks, J. & Zdunek, D. N-Terminal-proBNP (NT-proBNP) as an indicator of cardiac dysfunction. ZS Kardiologie 94, 247–254 (2005). https://doi.org/10.1007/s00392-005-0205-6

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-005-0205-6

Schlüsselwörter

Key words

Search

Navigation